The burden of Clostridioides difficile infection (CDI) has greatly increased. We evaluated the risks for CDI transmission to community members after hospitalized patients are discharged. We conducted a systematic literature review in MEDLINE/PubMed, EMBASE, Cinahl plus EBSCO, Web of Science, Cochrane Library, and gray literature during January 2000–February 2019 and identified 4,798 citations were identified. We eliminated 4,554 citations through title and abstract screening; 217 additional citations did not meet full criteria. We reviewed texts for the 27 remaining articles qualitatively for internal/external validity. A few identified studies describing risks to community members lacked accurate risk measurement or preventative strategies. Primary data are needed to assess efficacy of and inform current expertise-driven CDI prevention practices. Raising awareness among providers and researchers, conducting clinical and health services research, linking up integrated monitoring and evaluation processes at hospitals and outpatient settings, and developing and integrating CDI surveillance systems are warranted.

Clostridioides (the genus name of this bacterium was changed from Clostridium to Clostridioides during 2018) difficile infection (CDI) is responsible for almost half a million infections and ≈29,000 deaths in the United States annually (1). During 2000–2014, the number of hospitalizations from CDI increased from 134,518 to 361,945, and the financial contribution to inpatient healthcare expenditure increased from $0.5 billion to $3.9 billion (2). Risk factors for CDI and colonization include older age, recent hospitalization, recent use of antimicrobial drugs, and use of proton-pump inhibitors (3). Transmission of C. difficile occurs through the spread of spores primarily through environmental contamination, hands of healthcare personnel, and asymptomatic carriers (4). Several well-established guidelines recommend strategies in the inpatient setting to prevent and treat CDI. Prevention methods strongly recommended in the guidelines within an acute-care setting include isolating patients with CDI in private rooms with private toilets, using gloves and gowns when entering rooms with CDI patients, using soap and water when entering or exiting a CDI patient room, and cleaning reusable equipment with a sporicidal disinfectant (4).

For treatment, the 2017 update by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommends stopping causing antimicrobial drugs and using oral vancomycin or fidaxomicin, or intravenous metronidazole as a less preferred alternative, in most cases of CDI (4).

Although classically believed to be a hospital-acquired infection, C. difficile has also proven to be a major community pathogen. Although the 2017 IDSA/SHEA update recognizes the role of CDI in the community, it gives no specific prevention strategies to use at home (4). Community-acquired C. difficile might account for more than one third of total CDI cases, and patients tend to be younger and have less recent exposure to antimicrobial drugs and less exposure to healthcare settings than other persons who have CDI (5,6).
Because many patients hospitalized for CDI are discharged before completing full-course treatment or complete resolution of diarrhea, a common conundrum is deciding what prevention strategies are effective to be recommended at home after discharge to prevent the spread of infection to household or community contacts. Although substantial data and consensus guidelines exist for effective prevention strategies in the inpatient setting, similar data appear more sparse in the community setting. In this study, we systematically assessed data regarding the rate and role of the spread of C. difficile from an index hospitalized patient to the patient’s household members and community contacts. We also aimed to identify potential effective preventive strategies within the community.

Methods
For this study, we defined the population of interest as patients who had positive test results for CDI and who had another household member or contact with a patient who had previously been given a diagnosis of and treatment for C. difficile diarrhea. We defined a positive test result for CDI as a patient who had diarrhea sample that had positive results in a glutamate dehydrogenase antigen test, both toxin A and B tests, or a nucleic acid amplification test in the setting of either negative glutamate dehydrogenase test result or toxin A and B test results, or positive stool culture, regardless of diarrhea symptoms (i.e., active CDI vs. asymptomatic carrier).

Data Sources and Searches
We conducted a systematic review of literature in the databases MEDLINE, EMBASE, CINAHL plus EBSCO, Web of Science, PubMed, and The Cochrane Library, as well as gray literature, including abstracts/proceeding of gastroenterology, infectious disease, and related professional societies annual meeting, and guidelines by professional associations, all published during January 1, 2000–February 19, 2019. In addition to the primary literature search, we performed a snowballing method and checked references cited in current guidelines and the most relevant articles from our search. We developed a list of key search terms (Table 1) during multiple brainstorming sessions (including clinicians, contributors, and a specialized librarian) and through an extensive review of Medical Subject Headings (MeSH) terms from relevant articles identified through preliminary searches in PubMed. We divided the search terms into 2 search buckets, 1 centered around “Clostridium difficile” (all related MeSH terms and possible text words) and 1 centered around “carrier state” and “cross infection” (all related MeSH terms and possible text words). Furthermore, we used the OVID Medline strategy (Appendix, https://wwwnc.cdc.gov/EID/article/27/7/20-0209-App1.pdf) to search all databases by using appropriate thesaurus terms and natural language. The study was registered at the PROSPERO Registry as no. CRD42019118021 (study protocol provided in the Appendix).

Inclusion criteria were studies that defined laboratory testing for C. difficile detection or used and measured diarrheal episodes or used any test to detect infection; measured or included a contact or an exposure with patients previously given a diagnosis of C. difficile diarrhea in hospital settings; measured outcomes among outpatient or community persons who were exposed in the form of rates or number of events; and mentioned or described an actual intervention (treatment such as antimicrobial drugs for the CDI index case, which is hypothesized to decrease the period of infectiousness and subsequent transmission or a prevention strategy, such as handwashing and surface cleaning with sporidical.

Table 1. Search terms and databases used for systematic review of Clostridioides difficile infection*

| Bibliographic database | Search terms/condition | Search terms/carrier state |
|------------------------|------------------------|---------------------------|
| OVID MEDLINE           | Clostridioides difficile, Clostridium Infections, Clostridium adj4 poisoning, Clostridium Perfringens, Clostridium sordelli*, Infect* adj3 perfringen* | Carrier State, carrier and state, Cross infection, Cross and Infect*, infect* adj2 nosocomial |
| EMBASE                 | Clostridioides difficile, Clostridium Infections, Clostridial Disease, Clostridial Infection*, Clostridi*adj4 poisinin*, Clostredi* perfringen*, Clostri* Sordelli* | Carrier State, Cross Infection, Infect* and Cross, Infect* adj2 nosocomial |
| Web of Science         | Clostridioides difficile, Clostridium Infections, Clostridium Infection, Clostridium Poisoning, Clostridium perfringens, Clostridium Sordellii | Carrier State, Cross Infection, Nosocomial Infection, Nosocomial Infections |
| Cochrane Library       | Clostridioides difficile, Clostridium Infections, Clostridium Poisoning, Clostridium perfringens, Clostridium sordellii | Carrier State, Cross Infection, Nosocomial Infection, Nosocomial Infections |
| Gray literature        | Clostridium Infection | Cross Infection |

*Filters/limits were limit 2000–present and English language. Asterisks indicate truncation for other variations or modified versions of a searched word (e.g., shortened, misspelled, or differently spelled versions). This search includes all versions of Clostridi and Clostridioides difficile, including Clostridoides, which also are shown in citations used for this paper.
antiseptic and contact isolation). Exclusion criteria were nonhuman studies, studies not published in English, studies that did not specifically describe the study population, and studies that did not describe any form of CDI infection or did not reference any treatment or prevention strategy.

**Data Extraction, Quality Assessment, and Data Synthesis and Analysis**

We designed a 4-stage screening process to select the most relevant literature for review. First, we developed search terms along with a search algorithm and searched databases for articles containing the key search terms in their title or abstract. Second, we reviewed the titles and abstracts of these articles for exclusion and inclusion criteria. We examined whether a study had an index patient who had diarrhea caused by CDI in the hospital, an exposure that existed outside the hospital, an outcome after that exposure measured with laboratory tests or clinical diagnosis, and an intervention (either preventive or therapeutic) that was applied to the index patient or other exposed persons to protect against subsequent CDI at the community level. If there was no intervention, we set to record the rates of postexposure infection among contacts. Third, we qualitatively reviewed the full texts of the remaining articles that had not been excluded to confirm that they met the inclusion and exclusion criteria and to assess them for their sample size, outcome measures, biases, comparison of rates and outcomes, efficacy of their treatment or preventive measures, and internal/external validity.

We also applied a snowballing method by reviewing references and citations to current guidelines and panel of expert recommendations selected for the full text review. At the end of this process, we retrospectively read through all 217 articles from phase 2, even though they did not fully meet the inclusion criteria, to ensure that all potential relevant information was captured. We then organized and reported findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (7). A dedicated librarian with expertise in conducting systematic review performed the database search and imported search results into Covidence software (https://www.covidence.org) for review. Two reviewers screened the articles from stages 1 and 2 independently. Another tie-breaker reviewer looked at the articles that were discordant. The texts of remaining articles were reviewed by ≥2 reviewers.

**Results**

We found 4,798 articles through our search strategy. We compiled more detailed descriptions of search hits from specific databases (Table 2). After applying the exclusion criteria, we eliminated 4,554 articles through title and abstract screening. We screened the abstracts for the remaining 244 articles for inclusion criteria; we eliminated 217 of those for not meeting the full criteria. The full text of the remaining 27 articles were read to confirm eligibility (Figure).

None of the articles evaluated transmission of *C. difficile* from an infected person in the hospital to someone in the community, long-term acute care facility, nursing home, or subacute rehabilitation center. Some common reasons for eliminating articles included nonclinical studies that used computer modeling to study transmission, studies that only included exposure occurring within instead of outside the hospital, and studies that had no interventions described to prevent transmission. For example, one study interviewed 1,013 patients who had confirmed community-acquired *C. difficile* and showed that 11 patients had a household member with active CDI (6). Of patients with community-acquired CDI and no outpatient healthcare exposure, the odds ratio of having a household member with active CDI was 6.8 (95% CI 0.7–65.9) compared with patients who had high-level outpatient healthcare exposure (6). However, the study did not verify the

| Table 2. Results of literature review search on prevention and treatment/management of *Clostridioides difficile* infection to family members and community from an index hospital patient, by database, September 2019 |
|------------------|---------------------------------|------------------|------------------|-------------------------------------------------|
| Database        | Search strategy for prevention | Search strategy for management | Results | Key features of search engine                     |
| PubMed          | Full search                     | Full search       | 2,215           | Index to articles in medical journals and other selected biomedical literature |
| Cochrane Library | Full search                     | Full search       | 435             | Database of systematic reviews of primary research in human healthcare and health policy |
| Web of Science  | Search limited to 50 terms      | Search limited to 50 terms | 1,494           | Helpful for topics that border on social science |
| EMBASE          | Full search                     | Full search       | 1,653           | European alternative to PubMed; helpful for topics with an international focus |
| Gray literature | Full search                     | Full search       | 1               | Manifold document types produced on all levels of government, academics, business and industry in print and electronic formats. |
infectious status of the index patient and did not examine what was performed to prevent transmission to household contacts.

Another study examined household transmission for 2,222 patients who had confirmed C. difficile infection diagnosed at the Centre Hospitalier Universitaire de Sherbrooke (Sherbrooke, Quebec, Canada). The study identified 1,061 spouses and 501 children <25 years of age living with the index patients (8). Five spouses and 3 children developed C. difficile infection within a year after discharge of the index patients (attack rate 4.71 cases/1,000 persons for spouses and 5.99 cases/1,000 persons for children of index cases). Similar to the study of Chitnis et al. (6), this study did not define what isolation or prophylactic measures were taken to reduce transmission to household contacts. However, a more recent study by Miller et al. conducted among 194,424 enrollees, published after our original search was completed, indicated a 12.47 incidence rate ratio among household contacts of DCI patients discharged from tertiary care centers (9). In addition, Loo et al. evaluated probable transmission rates of 1.5% and possible transmission rates of 7.5% for household contacts of 51 CDI patients (10).

Some studies reported community-acquired CDI, but did not explicitly report an exposure to hospitalized patients who had C. difficile infection (11,12). For example, Bloomfield and Riley reported estimated rates of community acquired C. difficile infection in North America ranging from 20% to 32% (12). This study also showed that nonhuman reservoirs, including animals and food, have shown positive results for C. difficile infection. However, these findings have yet to be replicated by additional studies. Another source of community-associated C. difficile infection studied was healthcare exposure. For example, Chitnis et al. (6) showed that 82% of their patients had some exposure to healthcare within 12 weeks before infection, including outpatient dental or physician office visits and dialysis. They also showed known traditional risk factors: 64% used antimicrobial drugs within 12 weeks before infection, and 27.7% used proton pump inhibitors (Table 3).

We identified consensus articles from organizations, such as the International Infection Control Council, IDSA, and SHEA. In addition, the American Nursing Association endorses the approach of the Centers for Disease Control and Prevention, which in return endorses IDSA guidelines. Many recommendations were guided by expert opinion, rather than primary research on CDI transmission from the hospital setting to the community. Although many of the guidelines are not guided by primary research results, we highlighted some current inpatient practices for treating and preventing transmission of CDI in the inpatient setting (Table 4, https://wwwnc.cdc.gov/EID/article/27/7/20-0209-T4.htm).

Discussion

Increasingly, the extent and role of hospital-acquired infections, excessive use of antimicrobial drugs, drug-resistant bacterial infections, and decreased efficacy of common and available antimicrobial drugs as serious threat to individual and population health, and health agencies in the United States and elsewhere have called for measures to address these factors (17). C. difficile continues to be among the highest burden of hospital-acquired infections, such that IDSA, SHEA (4), the American College of Gastroenterology (13), and the European Society of Clinical Microbiology and Infectious Diseases (14,15), have all published guidelines for the preventing and managing of C. difficile in inpatient settings. Available
Table 3. Results of qualitative assessment of studies evaluating risk for CDI in the community*

| Study (reference) | Study type          | Year | Study No. (persons/studies) | Setting                      | Actual risk/assumed risk                                                                 | Intervention |
|-------------------|---------------------|------|-----------------------------|------------------------------|------------------------------------------------------------------------------------------|--------------|
| Pépin et al. (8)  | Retrospective       | 2012 | 2,222 C. difficile patients  | Household contacts           | Children attack rate: 4.71 cases/1,000 persons; spouse attack rate: 5.99 cases/1,000 persons | None         |
| Chitnis et al. (6) | Retrospective and telephone interview | 2013 | 984 community-acquired C. difficile patients | Household contacts | Odds of community-acquired CDI if no outpatient healthcare exposure: 6.8 (95% CI 0.7–65.9); odds of community-acquired CDI if low level outpatient healthcare exposure: 6.9 (95% CI 0.9–56.7) | None         |
| Durovic et al. (11)| Narrative review    | 2018 | 24 studies                  | Other healthcare facilities and community | Not measured                                                                              | None         |
| Bloomfield and Riley (12) | Narrative review | 2016 | NA                          | Household contacts           | Estimated rate of community acquired CDI in North America: 20%–32%                        | None         |
| Loo et al. (10)   | Prospective         | 2016 | 51                          | Household contacts           | Probable transmission: 1.5%; possible transmission: 7.5%                                | None         |
| Miller et al. (9) | Case–control        | 2020 | 194,424 enrollees            | Household contacts           | IRR 12.47 (95% CI 8.86–16.97)                                                            | None         |

*CDI, Clostridioides difficile infection; IRR, incidence rate ratio.

The reasons for this lack of data are likely multifactorial. A fragmented healthcare system does not provide opportunities to identify and record outpatient episodes and related illnesses associated with inpatient CDI diagnosis. In addition, no systematic approach has been established to collect data at the patient level through providers, and no public health tracing or follow-up process with family members exists. Departments of health at the state level do not routinely collect data related to CDI patients or subsequent infections (19). The providers caring for index or subsequently exposed patients often lack the instruction or support necessary for evaluating patients after hospital discharge and their family or community contacts. There might be low rates of secondary symptomatic infections in the household setting. Furthermore, there is probably a lack of recognition of the burden of CDI among outpatient health providers, and laboratory report systems are not in place to send reminders. Potential consequences of this lack of strong data include inadvertent transmission of CDI from the community back to the healthcare environment, increased financial cost to health system from treating preventable cases of secondary CDI, and probably an increasing
number of multidrug-resistant CDI. The Institute of Medicine has emphasized the burden of hospital-acquired infections and the need for systematic approaches and delineated framework and processes for moving forward (20,21).

We have provided a summary of current practices in the inpatient settings because we realize that in the absence of primary data, the recommended approaches need to include all levels of evidence to direct the actual practice. Nevertheless, the role of primary approaches, such as antimicrobial drug stewardship, could not be overemphasized. Furthermore, we suggest that a range of overarching initiatives is needed to address the risk and subsequent burden of transmission of CDI to the community. Perhaps the most useful area to focus on is the development of a monitoring and evaluation process in the hospital setting that can ensure that relevant data are available to outpatient providers at the time of discharging the index patient. Proper data collection processes should be added into the current system of collecting and monitoring health data by developing tools and reinforcing accurate documentation and tracking of CDI cases and their sequelae. A direct link between providers in the outpatient and hospital settings to identify and address subsequent CDI should not be overlooked. Simple strategies, such as follow-up telephone calls and gathering information from family members, could help determine the possibility or the extent of the disease at the patient level through similar initiatives commonly used for postsurgical interventions (22–27).

There is also a need for direct primary research on the feasibility and efficacy of specific CDI prevention and management strategies after hospital discharge. Prevalence studies evaluating outcomes at individual and household levels, and interventional cohorts, including different types of preventive or management strategies for CDI should be considered because they are likely to provide useful data.

We did not include studies published in languages other than English. However, our preliminary search did not identify this limitation as a major gap in evidence. Data regarding the efficacy of prevention strategies at the community level might exit in the form of reports and proposals developed in departments of health in or outside the United States that were not captured in our extensive systematic review.

Our systematic review indicates a need for research that evaluates the efficacy and effectiveness of various CDI prevention and management strategies after infected patients are discharged from inpatient settings. Ultimately, this research will enable the field of CDI and multidrug-resistant infections to transition from one that is largely extrapolative and expertise driven to one that is more evidence based. The current guidelines do not give any recommendations on how to prevent and manage CDI among family members and community contacts after hospital discharge of an index patient. However, guidelines do recommend assessment and monitoring, clearly emphasizing the need for good data and evidence. There are clearly challenges at the research and practice level that need to be systematically addressed. To start, perhaps there is a need to appropriately raise awareness of the problem among clinical providers and researchers. Concurrently, conducting related clinical and population level research, setting up and connecting monitoring and evaluation programs at hospital and outpatient settings, and developing CDI-related data within public health surveillance are warranted.

About the Author
Dr. Asgary is a clinical associate professor of Medicine at Weill Cornell College of Medicine, New York, NY, and associate professor of global health at George Washington University, Washington, DC. His primary research interests are health services, general medicine, and global health.

References
1. Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile Surveillance Team. Burden of *Clostridium difficile* infection in the United States. N Engl J Med. 2015;372:2369–70. https://doi.org/10.1056/NEJMa1408913
2. Lee RM, Fishman NO. Increasing economic burden of inpatient *Clostridium difficile* infection in the United States: national trends in epidemiology, outcomes, and cost of care from 2000 to 2014. Open Forum Infect Dis. 2017;4(Suppl 1):S392. https://doi.org/10.1093/ofid/ofx163.976
3. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for *Clostridium difficile* infection and colonization. N Engl J Med. 2011;365:1693–703. https://doi.org/10.1056/NEJMa1012413
4. McDonald LC, Gerverg DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–94. https://doi.org/10.1093/cid/ciy149
5. Khanna S, Pardi DS, Aronson SL, Kamper PP, Orenstein R, St Sauver JL, et al. The epidemiology of community-acquired *Clostridium difficile* infection: a population-based study. Am J Gastroenterol. 2012;107:93–95. https://doi.org/10.1038/aig.2011.398
6. Chitnis AS, Holzbauer SM, Bellflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated *Clostridium difficile* infection, 2009 through 2011.
SYNOPSIS

JAMA Intern Med. 2013;173:1359–67. https://doi.org/10.1001/jamainternmed.2013.7056

7. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097

8. Pépin J, Gonzales M, Valiquette L. Risk of secondary cases of *Clostridium difficile* infection among household contacts of index cases. J Infect. 2012;64:387–90. https://doi.org/10.1016/j.jinf.2011.12.011

9. Miller AC, Segre AM, Pemmaraju SV, Sewell DK, Polgreen PM. Association of household exposure to primary *Clostridioides difficile* infection with secondary infection in family members. JAMA Netw Open. 2020;3:e208925. https://doi.org/10.1001/jamanetworkopen.2020.8925

10. Loo VG, Brassard P, Miller MA. Household transmission of *Clostridium difficile* to family members and domestic pets. Infect Control Hosp Epidemiol. 2016;37:1342–8. https://doi.org/10.1017/ice.2016.178

11. Durovic A, Widmer AF, Tschudin-Sutter S. New insights into transmission of *Clostridium difficile*: a narrative review. Clin Microbiol Infect. 2018;24:483–92. https://doi.org/10.1016/j.cmi.2018.01.027

12. Bloomfield LE, Riley TV. Epidemiology and risk factors for community-associated *Clostridium difficile* infection: a narrative review. Infect Dis Ther. 2016;5:231–51. https://doi.org/10.1007/s40121-016-0117-y

13. Supawadi C, Brandt LJ, Binion DG, et al.; Committee. Guidance document for prevention of *Clostridium difficile* infection in acute healthcare settings. Clin Microbiol Infect. 2018;24:1051–4. https://doi.org/10.1016/j.cmi.2018.02.020

14. Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJ, Barbut F, Eckert C, et al.; Committee. Guidance document for prevention of *Clostridium difficile* infection in acute healthcare settings. Clin Microbiol Infect. 2018;24:1051–4. https://doi.org/10.1016/j.cmi.2018.02.020

15. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26. https://doi.org/10.1111/1469-0691.12418

16. Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of *Clostridioides* (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14. https://doi.org/10.1186/s13017-019-0228-3

17. Balsells E, Filipescu T, Kyaw MH, Wiuff C, Campbell H, Nair H. Infection prevention and control of *Clostridium difficile*: a global review of guidelines, strategies, and recommendations. J Glob Health. 2016;6:020410. https://doi.org/10.7189/jogh.06.020410

18. Shaughnessy MK, Bobr A, Kuskowski MA, Johnston BD, Sadowsky MJ, Khoruts A, et al. Environmental contamination in households of patients with recurrent *Clostridium difficile* infection. Appl Environ Microbiol. 2016;82:2686–92. https://doi.org/10.1128/AEM.03888-15

19. New York State Department of Health. Communicable disease reporting requirements, February 2011 [cited 2019 Oct 20]. https://www.health.ny.gov/forms/instructions/doh-389_instructions.pdf

20. US Institute of Medicine. Forum on emerging infections. Antimicrobial resistance: implications for global health and novel intervention strategies: Workshop summary. Washington (DC): National Academies Press; 1998.

21. US Institute of Medicine Forum on Microbial Threats. Antibiotic resistance: implications for global health and novel intervention strategies: Workshop summary. Washington (DC): National Academies Press; National Academies Press; 2010 [cited 2019 Nov 4]. https://www.ncbi.nlm.nih.gov/pubmed/21959116

22. Halwani MA, Turnbull AE, Harris M, Witter F, Perl TM. Postdischarge surveillance for infection following cesarean section: a prospective cohort study comparing methodologies. Am J Infect Control. 2016;44:455–7. https://doi.org/10.1016/j.ajic.2015.10.023

23. Koek MB, Wille JC, Isken MR, Voss A, van Benthem BH. Post-discharge surveillance (PDS) for surgical site infections: a good method is more important than a long duration. Euro Surveill. 2015;20:21042. https://doi.org/10.2807/1560-7917.ES2015.20.8.21042

24. Staszewicz W, Eisenring M-C, Bettschart V, Harbarth S, Troillet N. Thirteen years of surgical site infection surveillance in Swiss hospitals. J Hosp Infect. 2014;88:40–7. https://doi.org/10.1016/j.jhin.2014.06.003

25. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32. https://doi.org/10.1016/j.ajic.2008.03.002

26. Lima JL, de Aguiar RA, Leite HV, Silva HH, de Oliveira WM, Sacramento JP, et al. Surveillance of surgical site infection after cesarean section and time of notification. Am J Infect Control. 2016;44:273–7. https://doi.org/10.1016/j.ajic.2015.10.022

27. Petherick ES, Dalton JE, Moore PJ, Cullum N. Methods for identifying surgical wound infection after discharge from hospital: a systematic review. BMC Infect Dis. 2006;6:170. https://doi.org/10.1186/1471-2334-6-170

Address for correspondence: Ramin Asgary, Weill Cornell Medical College, 525 E 68th St, Baker 20th, F2008, New York, NY 10065, USA; email: ga263@columbia.edu
Appendix

PROSPERO Proposal

Table of Contents

Requirements

1. Review title
2. Original language title
3. Anticipated or actual start date
4. Anticipated completion date
5. Stage of review at time of this submission
6. Named contact
7. Named contact email
8. Named contact address
9. Named contact telephone number
10. Organizational affiliation of the review
11. Review team members and their organizational affiliations
12. Funding sources/sponsors
13. Conflicts of interest
14. Collaborators
15. Review question
16. Searches
17. URL to search strategy
18. Condition or domain being studied
19. Participants/population
20. Intervention(s), exposure(s)
21. Comparator(s)/control
22. Types of study to be included
23. Context
24. Main outcome(s)
25. Additional outcome(s)
26. Data extraction (selection and coding)
27. Risk for bias (quality) assessment
28. Strategy for data synthesis
29. Analysis of subgroups or subsets
30. Type and method of review
31. Language
32. Country
33. Other registration details
34. Reference and/or URL for published protocol
35. Dissemination plans
36. Keywords
37. Details of any existing review of the same topic by the same authors
38. Current review status
Proposal for Study

Review Title

Systematic review of *C. difficile* transmission to household contacts during transition in healthcare settings: the rate and significance of transmission

Original language title

English

Anticipated or actual start date

November 26, 2018

Anticipated completion date

June 1, 2019

Stage of review at time of this submission

Literature search

Named contact

Ramin Asgary, MD, MPH

Named contact email

raa9102@med.cornell.edu

Named contact address

525 East 68th

Box 331

New York, New York 10065

212–746–5924

Organizational affiliation of the review
Review team members and their organizational affiliations

Jessica Snead, PharmD, Principle Co-Investigator, [New-York Presbyterian Hospital], Marina Halim, Research Assistant [Arnold and Marie Schwartz College of Pharmacy, Long Island University], Judy Stribling [Weill Cornell Medicine], Ramin Asgary, MD, MPH, MSc, Principle Investigator, [Weill Cornell College of Medicine]

Funding sources/sponsors

None

Conflicts of interest

None

Collaborators

None

Review question

What is the rate and significance of transmission of *Clostridium difficile* from the index case of patients treated for *C. difficile* diarrhea to the patients’ household members and contacts?

Searches

MEDLINE, EMBASE, CINAHL plus EBSCO, Web of Science, PubMed, and The Cochrane Library (Cochrane Database of Systematic Reviews), Psychinfo, Google Scholar and gray literature including abstracts/proceeding of Gastroenterology, infectious disease and related professional societies annual meetings, as well as guidelines by professional associations using only the English language from January 2000 and beyond.

URL to search strategy

?

Condition or domain being studied

*Clostridium difficile*

Participants/population, intervention(s), exposure(s)
Inclusion Criteria

The population of interest would be patients who test positive for *Clostridium difficile* infection in the setting of another household member or contact having previously been given a diagnosis of and treatment for *Clostridium difficile* diarrhea. A positive test of *C. difficile* infection would be defined as patients with diarrhea testing positive for GDH antigen test, both toxin A and B test, or NAAT in the setting of either negative GDH antigen test or toxin A and B test, regardless of symptom of diarrhea (i.e., active *Clostridium difficile* infection versus asymptomatic carrier).

Exclusion Criteria

Nonhuman studies. Nonclinical studies. Studies that do not specifically describe the study population. Studies not published in English.

 Comparator(s)/control

Not applicable.

Types of study to be included

Nonclinical studies is excluded. All other studies including randomized, observational, case studies, case series, case reports, meta-analysis, and reviews.

Context

No restriction is planned on study settings

Main outcome(s)

Rate or incidence, and consequences of *Clostridium difficile* infection in household contact of a previously diagnosed and treated patient with *Clostridium difficile* infection.

Additional outcome(s)

Duration of time from and nature of exposure (household member with diagnosis and treatment for *Clostridium difficile* diarrhea) and positive test result for *Clostridium difficile* infection of patient

Patient characteristics of population of interest to determine risk profile and factors

Characteristics of exposure that increases risk for infection
Treatment shortcoming or characteristics of treatment or prevention strategies that increase or mitigate risk for infection

**Data extraction (selection and coding)**

**Selection of Studies**

Search results will be collated into a reference management software to establish a central database with duplicate records removed. Two reviewers will independently screen titles and abstracts for eligibility for selection. Full text of all eligible selections will be reviewed, with inclusion of articles agreed upon by both reviewers. Discrepancies in eligibility and selection will be resolved between both reviewers; a third-party reviewer will resolve any discrepancies that are not resolved by the former 2 reviewers.

**Risk for bias (quality) assessment**

The Cochrane Effective Practice and Organization of Care (EPOC) Review Group quality criteria and PRISMA methodology will be used to assess studies and minimize bias. A checklist for different relevant biases along with methods to ascertain them is developed and applied to all eligible studies.

**Strategy for data synthesis**

Both qualitative and quantitative methods will be used to analyze data. Qualitative and descriptive analysis will be used for all primary and secondary outcomes. Quantitative analysis is planned, when applicable and data available, for average rate/risks ascertainment/incidences. For efficacy of treatment for primary index patient or of risks, RevMan software will be used when data available and if applicable. Three research team members will be involved in analysis and majority vote will be used.

**Analysis of subgroups or subsets**

This is primarily a descriptive analysis. For primary, as well as secondary outcomes, when data available, subgroup analyses will include analyses of covariates and logistic regression for sex, age, duration of exposure, other characteristics of exposure for index case, household contact, and characteristics of initial index case’s treatment such as antibiotic choice and its route and its duration, and other preventive strategies.
Type and method of review
Systematic review

Language
English

Country
Any country

Other registration details
?

Reference and/or URL for published protocol
?

Dissemination plans
?

Keywords

*Clostridium difficile* (all related MeSH terms), community, household, patient, infection, transmission (exposure, contact), risk, rate, incidence, side effect, antibiotics (all MeSH terms), diarrhea and related mesh terms, treatment and related mesh term (fecal, transplant), prevention, infection control, duration and time (and related MeSH terms)

Details of any existing review of the same topic by the same authors
None

Current review status
Review completed

Any additional information

Details of final report/publications(s)

Search strategy for CDI in MedLine/OVID

OVID MedLine
1. Exp *Clostridium difficile/*

2. (clostridium difficile OR c diff).mp [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading work, keyword heading word, protocol, supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

3. Exp *Clostridium Infections/*

4. Clostridicum infect*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5. (clostridium adj4 poisoning).mp. [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

6. Clostridium perfringen*.mp [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, key heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier synonyms]

7. Clostridcum sordell*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

8. 9infect* adj3 sordell*).mp [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

9. (infect* adj3 perfringen*).mp. [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

10. One OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9

11. Exp Carrier State/

12. ((carrier and state*) OR (state* and carrier)). mp [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, unique identifier, synonyms]

13. Exp Cross Infection/

14. ((cross and infect*) or (infect* and cross)). mp. [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, unique identifier, synonyms]

15. (infect* adj2 nosocomial). mp [mp = title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

16. Eleven OR 12 OR 13 OR 14 OR 15

17. !0 AND 16

18. Limit 17 to yr = ”2000 –Current”

19. Limit 18 to English language